Mr. Secretary, Reclassify the Statin

a year ago

Reclassifying low-dose statins from prescription-only to over-the-counter (OTC) could significantly improve cardiovascular prevention in the U.S.
Scientific evidence shows that lowering LDL cholesterol reduces the risk of myocardial infarction or stroke by approximately 22% per mmol/L reduction.
Statins have a strong safety profile, with serious side effects like muscle injury and hepatotoxicity being extremely rare (<0.1%).
The UK has already made simvastatin 10 mg available OTC since 2004 without safety concerns, setting a precedent.
FDA rejections for OTC statins have focused on consumer competence rather than safety, despite technological solutions like web-apps showing high concordance between consumer and clinician judgment.
Even modest uptake (e.g., 1% of eligible adults) could prevent ~14,000 heart attacks and strokes, saving ~56,000 quality-adjusted life-years at minimal cost.
Statins like lovastatin are derived from natural sources (e.g., red-yeast-rice mold), making them comparable to supplements already available.
Proposal includes a phased approach: initial pharmacist-screened sales followed by full OTC availability after post-market data confirms safety.
Removing this regulatory barrier could provide a measurable public health win without new technology or significant funding.

Hasty Briefsbeta